In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cytogen's CytoRad (therap. and diag.) raises $32.5M in IPO

Executive Summary

Cytogen completed an IPO for CytoRad, its new spin-off which will concentrate on the development of four therapeutic and diagnostic products for prostate and bladder cancer. 3.5 million units were sold at $10 each, raising $32.5 million for CytoRad.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies